Cell Therapy Packaging Products and Services Market, 2021-2030: Distribution by Type of Therapy (T-cell Therapies, Dendritic Cell Vaccines, Stem Cell Therapies, NK Cell Therapies and Other ATMPs), Package Engineering Design (Primary and Secondary Packagin

Cell Therapy Packaging Products and Services Market, 2021-2030: Distribution by Type of Therapy (T-cell Therapies, Dendritic Cell Vaccines, Stem Cell Therapies, NK Cell Therapies and Other ATMPs), Package Engineering Design (Primary and Secondary Packaging), Scale of Operation (Clinical and Commercial) and Geography (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecast

1.1. SCOPE OF THE REPORT
Given their ability to treat a wide range of clinical conditions, advanced therapy medicinal products, including cell and gene therapies, have revolutionized the delivery of healthcare. Presently, more than 30 cell-based therapy products have received marketing approvals across various geographies, while more than 1,000 therapeutic candidates are under clinical evaluation. Considering the lucrative investment opportunity within this domain, several investors are actively supporting ongoing / future product development programs in this upcoming field of pharmacological interventions. In fact, there has been a 240% increase in investment activity, in terms of capital amount invested, between 2019 and 2020. However, the ultimate success of cell therapies is dependent on the safe and timely delivery of viable doses of therapeutic cells to the right patient. In this context, it is worth highlighting that drug product manufacturing, packaging and logistics operations involving cell therapies are both complex and challenging. Moreover, in order to ensure the stability of such products across the supply chain, specific temperature conditions (cryogenic, ambient or refrigerated) are required, in addition to specialized packaging material. Considering that most cell therapies are personalized, it is imperative that errors in labeling are avoided at all costs.

Given the need for costly and specialized equipment and the complexities associated with handling cell-based therapy products, innovators in the healthcare industry are likely to involve contract service providers for their drug product production, packaging and transportation requirements. Over time, regulators across the world, including the US Food and Drug Administration (FDA) and the International Air Transport Association (IATA), have established guidelines for the packaging, storage and transport of cell therapies. Since CMOs / CDMOs with the necessary capabilities to handle cell therapies are also likely to have established processes that comply with the current acceptable standards across different global regions, it is better for therapy developers to strategically partner with the aforementioned players instead of focusing on developing in-house capabilities. Presently, close to 60 companies claim to be offering cell therapy packaging services and associated products. In fact, it is estimated that close to 30% of drug substance and drug product related operations of advanced therapy medicinal products are already outsourced to capable CMOs / CDMOs. Further, over the last few years, several service providers have also forged strategic alliances among themselves, in order to further expand existing capabilities and augment their respective service offerings. Given the rising trend of outsourcing in the healthcare industry, and the ongoing efforts of service providers to further improve their portfolios, we believe that the cell therapy packaging products and services market is likely to evolve at a steady pace in the next few years.

The “Cell Therapy Packaging Products and Services Market by Type of Therapy (T-cell Therapies, Dendritic Cell Vaccines, Stem Cell Therapies, NK Cell Therapies and Other ATMPs), Package Engineering Design (Primary and Secondary Packaging), Scale of Operation (Clinical and Commercial) and Geography (North America, Europe, Asia Pacific and Rest of the World) , 2021-2030” report features an elaborate study of the current scenario and future opportunity within the cell therapy packaging products and services market. In addition, the report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
 An overview of the current market landscape of cell therapy packaging services providers, including a detailed analysis based on their year of establishment, company size, location of headquarters, package engineering design (primary and secondary), type of packaging (active and passive), packaging material (dry ice and liquid nitrogen), type of passive system used, temperature ranges supported, type of cells handled and additional services offered.
 A detailed assessment of the current market landscape of cell therapy packaging products, providing information on type of packaging container (bags, vials, shipping container and others), container fabrication material (plastic and others), storage temperature conditions, type of cells packed and usability of containers. In addition, the chapter highlights analysis of cell therapy packaging product provider(s), based on various parameters such as year of establishment, company size and location of headquarters and key players.
 An in-depth competitiveness analysis of cell therapy packaging service providers based in different geographies, by taking into consideration the service strength of a company (based on its experience), packaging portfolio (package engineering design, type of packaging, type of packaging material and temperature ranges supported) service portfolio (type of additional services offered) and company size (small, mid-sized and large companies).
 An analysis of the various partnerships established between cell therapy packaging providers and cell therapy developers, during the period, 2016-2021. It includes a brief description of various types of partnership models (namely service alliance, technology / platform integration agreement, merger and acquisition) adopted by stakeholders engaged in this domain. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year of partnership, type of partnership, purpose of partnership, type of service covered and geographical location of players involved in a partnership.
 A list of more than 250 cell therapy developers anticipated to partner with cell therapy packaging providers, which have been shortlisted on the basis of developer strength (based on company size), type of therapy and pipeline maturity (based on stage of development of drug candidate).
 A case study highlighting the companies that claim to have the required expertise and capabilities for development and manufacturing of cell therapies, along with the information on their year of establishment, company size, location of headquarters and location of manufacturing facility. In addition, the chapter presents analysis on type of cells manufactured, source of cells, scale of operation and manufacturing capabilities / services of the aforementioned companies.
 Detailed profiles of the key players offering cell therapy packaging services and products. Each profile includes a brief overview of the company, details on cell therapy service portfolio, information on cell therapy packaging product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and future growth potential of the cell therapy packaging providers market. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented across [A] type of therapy (T-cell therapies, dendritic cell vaccines, stem cell therapies, NK cell therapies and other advanced therapy medicinal products), [B] package engineering design (primary and secondary packaging), [C] scale of operation (clinical and commercial) and [D] geography (North America, Europe, Asia Pacific and Rest of the World)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

1.2. RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent views on various non-commercial trends emerging in this industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary sources of information.

1.3. KEY QUESTIONS ANSWERED
 Who are the leading players offering cell therapy packaging services and products?
 What are the key considerations and challenges associated with cell therapy packaging?
 Which partnership models are commonly adopted by stakeholders engaged in this industry?
 Which players are likely to partner with cell therapy packaging service and product providers?
 What factors are likely to influence the evolution of the cell therapy packaging service providers market?
 What are the likely future trends in cell therapy packaging services market?
 How is the current and future opportunity likely to be distributed across key market segments?

1.4. CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of cell therapy packaging providers market and its likely evolution in the short-mid to long term.

Chapter 3 provides a general introduction to the pharmaceutical filling and packaging, including information on types of pharmaceutical packaging. The chapter lays emphasis on cell therapy packaging, primary and secondary packaging of cell therapies. In addition, it discusses the key considerations and challenges associated with cell therapy packaging.

Chapter 4 features an overview of the current market landscape of cell therapy packaging services providers, including a detailed analysis on the year of establishment, company size and location of headquarters. In addition, the chapter highlights the analysis on the package engineering design (primary and secondary), type of packaging (active and passive), packaging material (dry ice and liquid nitrogen) and type of passive system used. Further, the chapter also presents analysis on temperature ranges supported, type of cells handled and additional services offered.

Chapter 5 presents a detailed assessment of the current market landscape of cell therapy packaging products, providing information on type of packaging container (bags, vials, shipping container and others), container fabrication material (plastic and others), storage temperature conditions, type of cells packed and usability of containers. In addition, the chapter highlights analysis of cell therapy packaging product provider(s), based on various parameters such as year of establishment, company size and location of headquarters and key players.

Chapter 6 includes profiles of the key players offering cell therapy packaging services and products. Each profile includes a brief overview of the company, details on cell therapy service portfolio, information on cell therapy packaging product portfolio, recent developments and an informed future outlook.

Chapter 7 presents in-depth competitiveness analysis of cell therapy packaging service providers based in different geographies, by taking into consideration the service strength of a company (based on its experience), packaging portfolio (package engineering design, type of packaging, type of packaging material and temperature ranges supported) service portfolio (type of additional services offered) and company size (small, mid-sized and large companies).

Chapter 8 provides an analysis of the various partnerships established between cell therapy packaging providers and cell therapy developers, during the period, 2016-2021. It includes a brief description of various types of partnership models (namely service alliance, technology / platform integration agreement, merger and acquisition) adopted by stakeholders engaged in this domain. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year of partnership, type of partnership, purpose of partnership, type of service covered and geographical location of players involved in a partnership.

Chapter 9 presents a list of more than 250 cell therapy developers anticipated to partner with cell therapy packaging providers, which have been shortlisted on the basis of developer strength (based on company size), type of therapy and pipeline maturity (based on stage of development of drug candidate).

Chapter 10 features a case study highlighting the companies that claim to have the required expertise and capabilities for development and manufacturing of cell therapies, along with the information on their year of establishment, company size, location of headquarters and location of manufacturing facility. In addition, the chapter presents analysis on type of cells manufactured, source of cells, scale of operation and manufacturing capabilities / services of the aforementioned companies.

Chapter 11 presents a detailed market forecast analysis, providing insights on the likely growth of continuous manufacturing equipment providers market for the period 2021-2030. In addition, the chapter presents the likely distribution of the projected future opportunity based on type of therapy (T-cell therapies, dendritic cell vaccines, stem cell therapies, NK cell therapies and other advanced therapy medicinal products), package engineering design (primary and secondary packaging), scale of operation (clinical and commercial) and geography (North America, Europe, Asia Pacific and Rest of the World).

Chapter 12 is a summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of cell therapy products and services market.

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix that provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES

The following companies and organizations have been included in the report.

1. 3P Biopharmaceuticals
2. A2 Biotherapeutics
3. A4P
4. AbClon
5. Abeona Therapeutics
6. AccuResearch Korea
7. Achilles Therapeutics
8. Adaptimmune Therapeutics
9. Adicet Bio
10. ADVATIS
11. Advent Biologics
12. Aegle Therapeutics
13. Aeon Therapeutics
14. AffyImmune Therapeutics
15. AGC Biologics
16. AgenTus Therapeutics
17. Akron Biologics
18. Alitalia
19. Allele Biotechnology and Pharmaceuticals
20. AlLife Medicine
21. Allogene Therapeutics
22. Almac
23. Almog
24. Altaco XXI
25. Angiocrine Bioscience
26. Anterogen
27. apceth Biopharma (acquired by Hitachi Chemical)
28. Arbele
29. Arcellx
30. Aseptic Technologies
31. Aspire Health Science
32. Astellas Pharma
33. Atara Biotherapeutics
34. Athersys
35. Atlantis Bioscience
36. Aurora Biopharma
37. Asutrianova
38. Autolus Therapeutics
39. Axis Biotec
40. Azidus
41. Baylx
42. Beijing Biohealthcare Biotechnology
43. Beijing Doing Biomedical
44. Beijing Sanwater Biological Technology
45. Bellicum Pharmaceuticals
46. BHI Therapeutic Sciences
47. Bio Elpida
48. Biocair
49. BioCardia
50. Bioceltech Therapeutics
51. BioCentriq
52. BioInno Bioscience
53. Bioinova
54. BioNTech Manufacturing
55. Bioquark
56. BioRestorative Therapies
57. Biotech & Pharma Logistics
58. Biowy
59. bluebird bio
60. BlueRock Therapeutics (acquired by Bayer)
61. Bone Therapeutics
62. BrainStorm Cell Therapeutics
63. Bristol Myers Squibb
64. Brooks Life Sciences
65. Bukwang Pharmaceutical
66. Caladrius Biosciences
67. Capricor Therapeutics
68. Carina Biotech
69. CARsgen Therapeutics
70. CAR-T (Shanghai) Biotechnology
71. Cartesian Therapeutics
72. Cartherics
73. Catalent Biologics
74. Celgene
75. Celixir
76. Cell and Gene Therapy Catapult
77. Cell Medica
78. Cell Therapies
79. CellBios
80. Cell-Easy
81. Cellectis
82. Cellerant Therapeutics
83. Cellex
84. Cellin Technologies
85. CellMP
86. CellProtect Nordic Pharmaceuticals
87. CellProthera
88. Cellular Biomedicine
89. Celonic
90. Celularity
91. Celyad Oncology
92. CENTOGENE
93. Cesca Therapeutics
94. CHA Biotech
95. Chiesi
96. China Immunotech (Beijing) Biotechnology
97. China Regenerative Medicine
98. Chongqing Precision Biotech
99. Clean Cells
100. Co.don
101. Cognate BioServices (acquired by Charles River Laboratories)
102. CoImmune
103. ColdStash
104. Cook MyoSite
105. Cook Pharmica
106. CORESTEM
107. Creative Biolabs
108. CRISPR Therapeutics
109. Critical Transport Solutions Australia
110. Cryo-Cell
111. CryoGene
112. CRYOPDP (acquired by Cryoport)
113. Cryoport
114. CSafe Global
115. Cynata Therapeutics
116. Cytiva
117. CytoMed Therapeutics
118. Cytopeutics
119. Cytovac
120. Dendreon Pharmaceuticals
121. DiscGenics
122. DWK Life Sciences
123. EHL Bio
124. ElevateBio
125. Eli Lilly
126. EpiBone
127. Eutilex
128. Ever Supreme Bio Technology
129. EVERSANA
130. EUMA Biotech
131. Fate Therapeutics
132. Ferrer Internacional
133. Fibrocell Science
134. Formula Pharmaceuticals
135. Fortress Biotech
136. Fosun Kite Biotechnology
137. Froceth
138. FUJIFILM Irvine Scientific
139. Gamida Cell
140. GC Cell
141. GE Healthcare
142. GenCure
143. Genenta Science
144. GenIbet Biopharmaceuticals
145. Genus Oncology
146. GigaGen
147. GlaxoSmithKline
148. Global Cell Med
149. Glycostem Therapeutics
150. Gracell Biotechnologies
151. GC Pharma
152. Greiner Bio-One
153. Gwo xi Stem Cell
154. Hebei Newtherapy BIo-Pharma technology
155. Hebei Senlang Biotechnology
156. Helix BioPharma
157. HemaCare
158. Hemostemix
159. Histocell
160. Hitachi Chemical
161. Holostem Terapie Avanzate
162. Hope Biosciences
163. Horizon Discovery
164. Hrain Biotechnology
165. iCell Gene Therapeutics
166. Icell Kealex Therapeutics
167. ICS
168. ilaya
169. Immatics
170. Immetacyte
171. Immune Therapeutics
172. Immuneel Therapeutics
173. Immunocore
174. Immunovative Therapies
175. IncoCell Tianjin
176. INNOFORCE
177. Innovative Cellular Therapeutics
178. Instant Systems
179. Instil Bio
180. Intellia Therapeutics
181. International Stem Cell
182. Invectys
183. Iovance Biotherapeutics
184. Ixaka
185. Janssen
186. Japan Regenerative Medicine
187. Japan Tissue Engineering
188. jCyte
189. Jiuzhitang Maker Cell Technology
190. Juno Therapeutics
191. Juventas Cell Therapy
192. JW Therapeutics
193. JW CreaGene
194. Kadimastem
195. KAEDI
196. Kangstem Biotech
197. KBI Biopharma
198. Kiadis Pharma
199. Kite Pharma
200. KLSMC Stem Cells
201. KSQ Therapeutics
202. K-Stem Cell
203. Kymanox
204. Lai
205. LATAM Cargo
206. Legend Biotech
207. Leucid Bio
208. LifeCell
209. Lineage Cell Therapeutics
210. Lion TCR
211. Living Pharma
212. Longeveron
213. Lonza
214. Lufthansa Cargo
215. Lykan Bioscience
216. Macopharma
217. Magellan Biologicals
218. Magenta Therapeutics
219. Marken
220. Marker Therapeutics
221. McKesson
222. Med Cell Bahamas
223. Medeor Therapeutics
224. Medigene
225. MEDINET
226. MEDIPOST
227. Medisix Therapeutics
228. Melbourne Stem Cell Centre
229. Meridigen Biotech
230. Mesoblast
231. Miltenyi Biomedicine
232. Minaris Regenerative Medicine
233. Minerva Biotechnologies
234. MingJu Therapeutics
235. Minovia Therapeutics
236. MNX Global Logistics
237. MolMed
238. Müller + Müller (acquired by DWK Life Sciences)
239. Multimmune
240. Mustang Bio
241. MVE Biological Solutions
242. Nanjing Bioheng Biotech
243. NanoCool
244. NantKwest
245. Nature Cell
246. NeuroGeneration
247. NextCell Pharma
248. Nikon CeLL Innovation
249. Nipro Europe Group Companies
250. Nkarta
251. NKMax America
252. Nohla Therapeutics
253. Noile-Immune Biotech
254. Noray Biosciences Group
255. Novadip Biosciences
256. Novartis
257. Novex Innovations
258. NuVasive
259. Obsidian Therapeutics
260. Ology Bioservices
261. Orca Bio
262. Orchard Therapeutics
263. OrganaBio
264. OriGen Biomedical
265. Orthofix
266. Osiris Therapeutics
267. Oxford Biomedica
268. PackGene Biotech
269. PACT Pharma
270. Parexel
271. Patheon
272. PeproMene Bio
273. Personalized Stem Cells
274. PersonGen BioTherapeutics
275. PharmaBio
276. Pharmicell
277. Phio Pharmaceuticals
278. Pluristem Therapeutics
279. Plus Therapeutics
280. Poseida Therapeutics
281. Precigen
282. Precision BioSciences
283. Promethera Biosciences
284. Protheragen
285. Provia Laboratories
286. Q Therapeutics
287. Quick
288. R3 Stem Cell
289. Regeneus
290. Regenexx
291. Reliance Life Sciences
292. ReNeuron
293. Riordan Technologies
294. Riyadh Pharma
295. ROHTO Pharmaceutical
296. Roslin Cell Therapies
297. Roylance Pharma
298. RTI Surgical
299. Rubius Therapeutics
300. S.Biomedics
301. SABZ Biomedicals
302. Saint-Gobain
303. Salvat
304. SanBio
305. Sangamo Therapeutics
306. SAVSU Technologies (acquired by BioLife Solutions)
307. SCHOTT
308. Sclnow Biotechnology
309. SCM Lifescience
310. Seattle Genetics
311. Seneca Biopharma
312. Sensei Biotherapeutics
313. Sentien Biotechnologies
314. Sequel Logistics
315. Servier
316. Sexton Biotechnologies
317. SGD Pharma
318. Shandong Qilu Stem Cells Engineering
319. Shanghai Biomed-Union Biotechnology
320. Shanghai GeneChem
321. Shanghai iCELL Biotechnology
322. Shanghai Longyao Biotechnology
323. Shenzhen Binde Biotechnology
324. Shenzhen Hornetcorn Biotechnology
325. Sinobioway Cell Therapy
326. SiO2 Materials Science
327. SMT Bio
328. Sorrento Therapeutics
329. SOTIO
330. S-RACMO
331. Stem Cell Medicine
332. Stem Med
333. STEMCELL Technologies
334. Stemedica Cell Technologies
335. Steminent Biotherapeutics
336. Stemmatters
337. Stempeutics Research
338. Stryker
339. Sumitomo Dainippon Pharma
340. Suzuken
341. Swiss Medica XXI Century
342. Swiss WorldCargo
343. Tactiva Therapeutics
344. Taiwan Bio Therapeutics
345. Takara Bio
346. Takeda Pharmaceutical
347. Talaris Therapeutics
348. Targazyme
349. TC BioPharm
350. TCR2 Therapeutics
351. Technoflex
352. Teneobio
353. Terumo
354. Tessa Therapeutics
355. The Emmes Company
356. Thermo Fisher Scientific
357. Tianhe Stem Cell Biotechnologies
358. Tianjin Ever Union Biotechnology
359. Tianjin Mycure Medical Technology
360. Tianjin Weikai Biological Engineering
361. TICEBA
362. TiGenix
363. TILT Biotherapeutics
364. time:matters
365. Timmune Biotech
366. Tissue Solutions
367. Tmunity Therapeutics
368. TPP Techno Plastic Products
369. TrakCel
370. TreeFrog Therapeutics
371. Tscan Therapeutics
372. TVAX Biomedical
373. U.S. Stem Cell
374. Ucardi Biomedical Technology
375. United Cargo
376. United Parcel Services (UPS)
377. United Therapeutics
378. University College of London
379. Unum Therapeutics
380. UWELL Biopharma
381. va-Q-tec
382. VcanBio Center for Translational Biotechnology
383. Vericel
384. VetStem Biopharma
385. ViaCyte
386. Vineti
387. Viscofan BioEngineering
388. Vitalant
389. Waisman Biomanufacturing
390. Wellington Zhaotai Therapies
391. West
392. West Biotherapy
393. World Courier
394. Wugen
395. WuXi Advanced Therapies
396. Xiangxue Life Sciences
397. Yourway
398. Zelluna Immunotherapy
399. Zumutor Biologics

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.